At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
HB-adMSCsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
In Brief
A Phase 2 clinical trial evaluating HB-adMSCs for Traumatic Brain Injury. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This study aims to determine the safety of HB-adMSC infusion and treatment effects of HB-adMSC infusion on brain structure, neurocognitive/functional outcomes, and neuroinflammation after subacute and chronic neurological injury in adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTraumatic Brain Injury
CountriesUnited States
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartJan 2020
Primary CompletionOct 2024
TodayJul 2026
First PostedAug 21, 2019
Enrollment StartJan 1, 2020
Primary CompletionOct 25, 2024
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 6.9 years ago
Interventions
HB-adMSCsbiological
Hope Biosciences autologous adipose-derived mesenchymal stem cells